ATE246196T1 - Sulphostinanaloga und verfahren zur herstellung von sulphostin und analoga davon - Google Patents

Sulphostinanaloga und verfahren zur herstellung von sulphostin und analoga davon

Info

Publication number
ATE246196T1
ATE246196T1 AT00925639T AT00925639T ATE246196T1 AT E246196 T1 ATE246196 T1 AT E246196T1 AT 00925639 T AT00925639 T AT 00925639T AT 00925639 T AT00925639 T AT 00925639T AT E246196 T1 ATE246196 T1 AT E246196T1
Authority
AT
Austria
Prior art keywords
sulphostin
analogue
producing
respeetively
chem
Prior art date
Application number
AT00925639T
Other languages
English (en)
Inventor
Tomio Takeuchi
Yasuhiko Muraoka
Masatoshi Abe
Tetsuo Akiyama
Shigeko Harada
Original Assignee
Zaidan Hojin Biseibutsu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zaidan Hojin Biseibutsu filed Critical Zaidan Hojin Biseibutsu
Application granted granted Critical
Publication of ATE246196T1 publication Critical patent/ATE246196T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/5532—Seven-(or more) membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/568—Four-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)
  • Nonmetallic Welding Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Seasonings (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
AT00925639T 1999-05-17 2000-05-12 Sulphostinanaloga und verfahren zur herstellung von sulphostin und analoga davon ATE246196T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP13585499A JP4121215B2 (ja) 1999-05-17 1999-05-17 スルフォスチン類縁体、並びにスルフォスチン及びその類縁体の製造方法
PCT/JP2000/003055 WO2000069868A1 (en) 1999-05-17 2000-05-12 Sulphostin analogues and processes for the preparation of sulphostin and analogues thereof

Publications (1)

Publication Number Publication Date
ATE246196T1 true ATE246196T1 (de) 2003-08-15

Family

ID=15161335

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00925639T ATE246196T1 (de) 1999-05-17 2000-05-12 Sulphostinanaloga und verfahren zur herstellung von sulphostin und analoga davon

Country Status (8)

Country Link
US (1) US6579989B1 (de)
EP (1) EP1184388B1 (de)
JP (1) JP4121215B2 (de)
AT (1) ATE246196T1 (de)
CA (1) CA2372068A1 (de)
DE (1) DE60004217T2 (de)
ES (1) ES2199826T3 (de)
WO (1) WO2000069868A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
WO2002055088A1 (en) * 2001-01-16 2002-07-18 Nippon Kayaku Kabushiki Kaisha Remedies for bone marrow suppression and infectious diseases and white blood cell count elevating agents
CN1990469A (zh) 2001-06-27 2007-07-04 史密丝克莱恩比彻姆公司 作为二肽酶抑制剂的氟代吡咯烷
EP1457494A4 (de) * 2001-12-17 2006-04-12 Nippon Kayaku Kk Verfahren zur herstellung von sulphostin und dessen analoga oder zwischenprodukten davon
WO2003080633A1 (fr) * 2002-03-25 2003-10-02 Nippon Kayaku Kabushiki Kaisha Nouveau derive d'$g(a)-amino-n-(diaminophosphinyl)lactame
JP2004026678A (ja) * 2002-06-24 2004-01-29 Microbial Chem Res Found ２型糖尿病治療剤
US7355049B2 (en) * 2003-06-24 2008-04-08 Hoffmann-La Roche Inc. Biaryloxymethylarenecarboxylic acids as glycogen synthase activator
ATE550656T1 (de) * 2003-08-20 2012-04-15 Alere San Diego Inc Verfahren und zusammensetzungen zur messung biologisch aktiver natriuretischer peptide und zur verbesserung ihres therapeutischen potentials
WO2005027934A1 (ja) * 2003-09-24 2005-03-31 Nippon Kayaku Kabushiki Kaisha プロリルオリゴペプチダーゼ阻害剤
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
JP4915833B2 (ja) * 2005-07-01 2012-04-11 雪印メグミルク株式会社 ジペプチジルペプチダーゼｉｖ阻害剤
BRPI0710597A2 (pt) 2006-04-11 2012-06-19 Arena Pharm Inc método de uso do receptor gpr119 para identificar compostos úteis para aumento da massa óssea em um indivìduo
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
JP5148941B2 (ja) * 2007-07-11 2013-02-20 公益財団法人微生物化学研究会 スルフォスチン、及びスルフォスチン関連化合物を有効成分とした抗腫瘍剤
EP2108960A1 (de) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Verfahren zur Verwendung eines A G Protein-gekoppelten Rezeptors zur Identifikation von Peptid YY (PYY) Sekretagoga und nützliche Verbindungen zur Behandlung von durch (PYY) Sekretagoga modulierten Zuständen und nützliche Verbindungen zur Behandlung von Zuständen durch PYY
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
CN102470166B (zh) 2009-08-03 2014-04-09 株式会社钟化 二肽基肽酶-4抑制剂
WO2011127051A1 (en) 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
SG188548A1 (en) 2010-09-22 2013-04-30 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
MX386778B (es) 2015-03-09 2025-03-19 Intekrin Therapeutics Inc Métodos para el tratamiento de enfermedad de hígado graso no alcohólico y/o lipodistrofia.
WO2018187350A1 (en) 2017-04-03 2018-10-11 Coherus Biosciences Inc. PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH120357A (de) 1956-04-05 1927-06-01 Siemens Schuckertwerke Gmbh Elektromagnetischer Selbstausschalter, insbesondere in Stöpselform.
CH570113A5 (de) 1972-07-13 1975-12-15 Ciba Geigy Ag
US4723002A (en) 1986-04-28 1988-02-02 E. R. Squibb & Sons, Inc. 1-(substituted phosphorous)-azetidinone antibacterials
DE69839279T2 (de) * 1997-11-18 2009-05-28 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Neue physiologisch aktive substanz sulphostin, herstellung und verwendung derselben

Also Published As

Publication number Publication date
ES2199826T3 (es) 2004-03-01
EP1184388A1 (de) 2002-03-06
EP1184388A4 (de) 2002-10-16
DE60004217T2 (de) 2004-06-03
JP4121215B2 (ja) 2008-07-23
DE60004217D1 (de) 2003-09-04
JP2000327689A (ja) 2000-11-28
US6579989B1 (en) 2003-06-17
EP1184388B1 (de) 2003-07-30
WO2000069868A1 (en) 2000-11-23
CA2372068A1 (en) 2000-11-23

Similar Documents

Publication Publication Date Title
ATE246196T1 (de) Sulphostinanaloga und verfahren zur herstellung von sulphostin und analoga davon
ATE120644T1 (de) Verwendung von 1,3-oxathiolanalogen von nukleosiden zur herstellung eines arzneimittels zur behandlung von hepatitis-b.
DE69915004D1 (de) 5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate
ATE302180T1 (de) Zwischenprodukte zur herstellung von non-peptiden retroviralproteasehemmenden verbindungen
ATE160341T1 (de) Benzolsulfonamid-derivate und verfahren zur herstellung
ATE502932T1 (de) Makrocyclische analoga und verfahren zu ihrer verwendung und herstellung
DE69817802D1 (de) Substituierte phenylderivate, ihre herstellung und verwendung
ATE132145T1 (de) Verfahren zur herstellung von bacchatin iii und von desacetyl-10-bacchatin iii derivate
NO20014925D0 (no) Farmasöytiske forbindelser
DE69521615D1 (de) Streptogramine in gereinigter form, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen
ATE163645T1 (de) Eintopfverfahren zur herstellung von 3- chinoloncarbonsäurederivaten
ATE142641T1 (de) Neue peptid-verbindungen und verfahren zur herstellung davon
ATE181066T1 (de) Zwischenverbindungen zur herstellung von thioalkylthio cephalosporinderivaten
DE69431035D1 (de) 2-Phenyl-3-Azoylbenzothiophene zur Erhöhung der Thrombomodulin Expression
DE69231815D1 (de) Verfahren zur Herstellung von Cephalosporinen und Zwischenprodukte in diesem Verfahren
ATE79257T1 (de) Verwendung von tetrahydrobenz(c,d>indol-6carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden.
FI935800A0 (fi) Antidepressiva och mot Parkisons sjukdom verksamma foereningar
EP0342587A3 (de) Thienotriazolodiazepine und ihre pharmazeutische Verwendung
NO20051282L (no) Antitumorale analoger av lamellariner.
FI952420A0 (fi) Glukopyranosidibentsotiofeenit
DE60224884D1 (de) Verfahren zur herstellung von 3, 3', 6, 6'-tetraalkylen-2, 2'-biphenolen und 3, 3', 6, 6'-tetraalkylen-5, 5'-dihalo-2, 2' biphenolen
NO173991C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 1,2,5-ditiazocin-derivater
FI930462A0 (fi) Aminobensoesyraderivat
DK0551844T3 (da) Svovlholdige galdesyrederivater
DE69827706D1 (de) 5-(Heteroaryl)alkyl)-3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid (PBI) Derivate zur Behandlung von Störungen des zentralen Nervensystems

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties